Format

Send to

Choose Destination
Acta Obstet Gynecol Scand. 1993 Jul;72(5):369-73.

Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas.

Author information

1
L. Mangiagalli Department of Obstetrics and Gynecology, University of Milano School of Medicine, Italy.

Abstract

OBJECTIVE:

To investigate the effect of gonadotropin releasing hormone agonist (goserelin) treatment before hysterectomy for leiomyomata-associated menorrhagia.

DESIGN:

Prospective, comparative, nonrandomized study.

SETTING:

A teaching hospital of Milano University.

PATIENTS:

Anemic women requiring hysterectomy for myoma-associated menorrhagia.

INTERVENTION:

Six months' preoperative goserelin treatment (41 cases) or immediate surgery (92 controls).

MAIN OUTCOME MEASURES:

Abdominal/vaginal hysterectomy rate, number of transfusions, operating time, blood loss, complications, febrile morbidity, and days in hospital.

RESULTS:

In the goserelin group mean hemoglobin rose (8.5 versus 13.3 g/dl) and mean uterine volume decreased (528 versus 251 ml). At preoperative pelvic exploration abdominal hysterectomy was indicated in 22 (54%) cases and 74 (80%) controls and vaginal hysterectomy in 19 (46%) and 18 (20%) (relative risk 3.6, 95% confidence interval 1.6 to 7.7; p = 0.001). No case required a transfusion whereas 51% of controls needed a total of 127 packed red cell units.

CONCLUSIONS:

In anemic women with menorrhagia and leiomyomas, gonadotropin releasing hormone agonist treatment before hysterectomy limited transfusion requirements and increased the vaginal procedure rate.

PMID:
8392268
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center